Adagene Inc (ADAG NASDAQ) stock market data APIs
$1.7611
0.07(4%)
as of October 17, 2025
Try our APIs with
free plan!
Adagene Inc Financial Data Overview
Price chart is built with
Anychart
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Prev. Close
1.7611
Open
1.8306
High
1.8456
Low
1.7611
52 wk Range
1.325-3.16
Market Cap
82 951 K
Shares Outstanding
47 131 K
Revenue
103 K
EPS
-0.23
Beta
0.737
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adagene Inc data using free add-ons & libraries
Get Adagene Inc Fundamental Data
Adagene Inc Fundamental data includes:
- Net Revenue: 103 K
- EBITDA: -32 765 248
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.33
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adagene Inc News
New
CD47 Inhibitors Drug Market & Clinical Trials Insight 2026, Featuring Adagene, Akeso, ALX Oncology, EpicentRx, ImmuneOncia, ImmuneOnco Biopharma, Phanes Therapeutics, Virtuoso Therapeutics, and More
Company Logo The CD47-targeted therapy market is poised for growth due to its potential in treating resistant cancers. With over 80 drugs in trials, innovations like bispecific antibodies, combinatio...
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adagene Inc. Sponsored ADR (ADAG) is a stock that can certainly grab the attention o...
Could Access to SAFEbody Technology Shift Exelixis (EXEL) Pipeline Strategy in Oncology?
On September 16, 2025, Adagene Inc. announced an amendment to its 2021 collaboration and license agreement with Exelixis, allowing Exelixis to use Adagene's SAFEbody technology platform to generate a ...
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Adagene Inc. SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement w...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
